A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer
- PMID: 35016887
- DOI: 10.1016/j.clgc.2021.12.004
A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer
Keywords: Immune checkpoint inhibitors; Neo-adjuvant therapy; Prostate cancer; Surgery.
Conflict of interest statement
Disclosure M.S.v.d.H. has received research support from Bristol-Myers Squibb, AstraZeneca and Roche and consultancy fees from Bristol-Myers Squibb, Merck, Roche, AstraZeneca, Seattle Genetics and Janssen (all paid to the Netherlands Cancer Institute). J.M.d.F has an advisory role for Merck Sharp & Dohme, Pfizer, and Janssen and travel expenses are covered by Pfizer. B.W.G.v.R is active in advisory boards with AstraZeneca, Ferring and QED Therapeutics. The other authors report no conflict of interest relevant to this work. Bristol-Myers Squibb was not involved in the concept and design of the work presented in this manuscript, but did provide approval of the manuscript.
Similar articles
-
Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.JAMA Netw Open. 2021 Dec 1;4(12):e2136823. doi: 10.1001/jamanetworkopen.2021.36823. JAMA Netw Open. 2021. PMID: 34854905 Free PMC article.
-
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.Br J Dermatol. 2020 Sep;183(3):559-563. doi: 10.1111/bjd.18739. Epub 2019 Dec 26. Br J Dermatol. 2020. PMID: 31773720
-
Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.Eur J Dermatol. 2021 Oct 1;31(5):662-664. doi: 10.1684/ejd.2021.4139. Eur J Dermatol. 2021. PMID: 34642136 No abstract available.
-
Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.Future Oncol. 2019 Feb;15(4):349-358. doi: 10.2217/fon-2018-0607. Epub 2018 Oct 18. Future Oncol. 2019. PMID: 30334646 Review.
-
Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.Clin Transl Oncol. 2021 Sep;23(9):1885-1904. doi: 10.1007/s12094-021-02598-6. Epub 2021 Apr 20. Clin Transl Oncol. 2021. PMID: 33877531
Cited by
-
Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.Front Immunol. 2023 Jul 3;14:1196829. doi: 10.3389/fimmu.2023.1196829. eCollection 2023. Front Immunol. 2023. PMID: 37465665 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical